Salute e Benessere
Postherpetic Neuralgia Market to Accelerate Significantly at a CAGR of 14% by 2034 | DelveInsight
Discover which therapies are expected to grab the major postherpetic neuralgia market share @
Postherpetic neuralgia is a frequent complication of shingles, which arises from the reactivation of the varicella-zoster virus (VZV) that remains dormant in the body after an initial varicella infection. The shingles outbreak damages sensory nerves, causing abnormal signals to be sent to the brain and resulting in pain. This condition often includes symptoms like dysesthesia, paresthesia, allodynia, and hyperalgesia. These symptoms can persist for many years, severely disrupting sleep, mood, and overall quality of life.
Apart from old age and immunosuppression, conditions such as systemic lupus erythematosus, diabetes, and recent trauma can increase the risk of developing postherpetic neuralgia. Factors such as advanced age, severe acute pain during the initial shingles infection, a rash spreading beyond the initial dermatome, and a weakened immune system contribute to a higher risk.
For diagnosing postherpetic neuralgia, the history of herpes zoster and the characteristics of the pain are crucial. Pain intensity and quality should be measured using an appropriate scale like a numerical rating scale, a visual analog scale, or a verbal descriptor scale (e.g., McGill Pain Questionnaire), depending on the patient's communication ability. Viral culture or immunofluorescent staining may help differentiate herpes simplex from herpes zoster.
Among the 7MM, the United States accounted for the highest number of incident cases of PHN, i.e., cases in 2023. According to estimates, PHN is slightly more common in females than males, accounting for of the total cases, while males accounted for of the total population share.
The postherpetic neuralgia market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:
The management of postherpetic neuralgia should focus on controlling pain and reducing adverse effects from treatments. Pain relief is complex and should involve medications, interventional procedures, and non-drug therapies. Guidelines suggest first-line treatments with calcium channel α2-δ ligands (such as ), tricyclic antidepressants (including ), or topical lidocaine patches. Opioids and topical capsaicin (in patch or cream form) are recommended as second-line treatments or as part of combination therapies with different mechanisms of action. Some patients may continue to experience pain despite using pharmacological, topical, psychological, and physical therapies. In such refractory cases, paravertebral and sympathetic nerve blocks can be considered.
The use of opioids as a primary treatment for neuropathic pain, including postherpetic neuralgia, is still a topic of debate. In the United States , the CDC recommends that healthcare providers restrict opioid prescriptions to cancer-related conditions and a few other serious health issues. For postherpetic neuralgia, topical lidocaine therapy, available in a patch form, has been approved in the United States , Europe , and Australia , and is recommended by the International Association for the Study of Pain. , a specialized 1.8% lidocaine topical system developed by , received FDA approval in 2018. However, in Japan , topical lidocaine therapy for postherpetic neuralgia has not been approved, though hospitals are preparing lidocaine gels for this condition.
Learn more about the FDA-approved drugs for postherpetic neuralgia @
Key players such as , and others are currently working with their lead assets to improve the postherpetic neuralgia treatment landscape.
, developed by , is a powerful, orally administered selective small molecule inhibitor targeting adaptor-associated kinase 1 (AAK1). Discovered through Lexicon's innovative gene science techniques, preclinical studies showed that mice lacking AAK1 had increased resistance to neuropathic pain. Identified through a neuroscience drug discovery partnership with Bristol Myers Squibb, Lexicon holds exclusive development and commercialization rights for LX9211. The company completed a Phase II clinical trial (NCT04662281; RELIEF-PHN1) of LX9211 for postherpetic neuralgia in adults, with results announced in December 2022 . Although the primary endpoint was not met, the trial provided clear evidence of LX9211's effect.
, developed by , has been approved in over 75 countries for treating upper and lower limb spasticity, cervical dystonia, blepharospasm, glabellar lines, and sialorrhea. This medication targets peripheral cholinergic nerve endings, reducing voluntary muscle contraction and relieving muscle tone by inhibiting the release of acetylcholine. XEOMIN is free of complex proteins, which lowers the risk of neutralizing antibody formation. Currently, Merz Therapeutics is conducting a Phase II PaiNT trial (NCT06091020) to evaluate the efficacy and safety of subcutaneous NT 201 injections compared to placebo in reducing pain intensity in adults with moderate to severe chronic peripheral neuropathic pain resulting from postherpetic neuralgia or peripheral nerve injury.
The anticipated launch of these emerging therapies for postherpetic neuralgia are poised to transform the market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the postherpetic neuralgia market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.
Discover more about postherpetic neuralgia drugs in development @
The dynamics of the postherpetic neuralgia market are expected to change in the coming years. Within the initial treatment choices, there is a
due to their localized action, minimal systemic presence, and decreased likelihood of drug interactions.
has multiple advantages over currently available , such as demonstrated superior bioavailability, adhesion to the skin, and drug delivery efficiency that increases its uptake.
The PHN market exhibits a scarcity of emerging players in its , presenting an advantageous opportunity for companies entering this segment. with reduced adverse effects compared to existing therapies could yield substantial benefits for these companies. Additionally, of the substantial burden of Herpes Zoster and PHN on QoL is essential and may improve prevention and management strategies.
Furthermore, many potential therapies are being investigated for the treatment of postherpetic neuralgia, and it is safe to predict that the treatment space will significantly impact the postherpetic neuralgia market during the forecast period. Moreover, the with improved efficacy and a further are expected to drive the growth of the postherpetic neuralgia market in the 7MM.
However several factors may impede the growth of the postherpetic neuralgia market. Despite notable advancements, the , and the efficacy of existing treatments is unsatisfactory, hampering postherpetic neuralgia therapeutic space. As the , an increasing number of individuals are at and subsequently experiencing PHN.
may face competition from manufactured by , as well as from . Inconsistent findings on the for PHN pose a challenge, making it confusing for patients and physicians to select the most reliable treatment.
Moreover, postherpetic neuralgia treatment poses a and disrupts patients' overall well-being and QOL. Furthermore, the postherpetic neuralgia market growth may be offset by , , , and a . In addition, the about the disease may also impact the postherpetic neuralgia market growth.
To know more about postherpetic neuralgia treatment guidelines, visit @
report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key postherpetic neuralgia companies, including among others.
report delivers an in-depth understanding of the disease, historical and forecasted postherpetic neuralgia epidemiology in the 7MM, i.e., the United States , EU5 ( Germany , Spain , Italy , France , and the United Kingdom ), and Japan .
report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key herpes zoster companies, including among others.
report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key herpes zoster companies, including among others.
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve
Shruti Thakur
info@delveinsight.com
+14699457679
www.delveinsight.com
Logo: https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/postherpetic-neuralgia-market-to-accelerate-significantly-at-a-cagr-of-14-by-2034--delveinsight-302168041.html